SK Biopharmaceuticals Co., Ltd. (KRX:326030)

SK Biopharmaceuticals Revenue

SK Biopharmaceuticals had revenue of 247.37B KRW in the quarter ending June 30, 2026, with 40.33% growth. This brings the company's total for the last twelve months to 861.34B, up 38.86% year-over-year. In the year 2025, SK Biopharmaceuticals had annual revenue of 706.74B with 29.06% growth. That makes SK Biopharmaceuticals the 9,763rd largest company in the world by revenue and 445th in South Korea.

• Revenue (ttm): 861.34B
• Revenue Growth: +38.86%
• P/S Ratio: 6.99
• Revenue / Employee: 3.50B
• Employees: 246
• Market Cap: 6.02T

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• United States of America 642.66B 90.9%
• Switzerland 33.25B 4.7%
• Japan 12.91B 1.8%
• Malta 11.38B 1.6%
• Cayman Islands 4.17B 0.6%
• Other Countries 2.27B 0.3%
• Korea 100.00M 0.0%

Fiscal year ended Dec 31, 2025 See the full SK Biopharmaceuticals breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	706.74B	159.14B	29.06%
Dec 31, 2024	547.60B	192.70B	54.30%
Dec 31, 2023	354.89B	108.71B	44.16%
Dec 31, 2022	246.18B	-172.47B	-41.20%
Dec 31, 2021	418.64B	392.65B	1,510.23%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 20, 2026

Data Sources Report a data error